JO3641B1 - تركيبة مضادات الفيروسات القهقرية - Google Patents

تركيبة مضادات الفيروسات القهقرية

Info

Publication number
JO3641B1
JO3641B1 JOP/2013/0141A JOP20130141A JO3641B1 JO 3641 B1 JO3641 B1 JO 3641B1 JO P20130141 A JOP20130141 A JO P20130141A JO 3641 B1 JO3641 B1 JO 3641B1
Authority
JO
Jordan
Prior art keywords
present
antiretroviral composition
aids
composition
antiretroviral
Prior art date
Application number
JOP/2013/0141A
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of JO3641B1 publication Critical patent/JO3641B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بتركيبة صيدلانية من الرذاذ الصلب تعطى عن طريق الفم تتضمن واحد أو أكثر من عقاقير مضادة للنسخ العكسي الفيروسي، و طريقة تصنيعها. و يعد الختراع الحالي مفيدا على وحه الخصوص في علاج الإصابة بعدوى ال </span>HIV<span dir="RTL">، أو المعقد ذات الصلة </span>AIDS <span dir="RTL"> أو </span>AIDS<span dir="RTL">.</span>
JOP/2013/0141A 2012-05-03 2013-05-05 تركيبة مضادات الفيروسات القهقرية JO3641B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1380MU2012 2012-05-03
IN2590MU2012 2012-09-06

Publications (1)

Publication Number Publication Date
JO3641B1 true JO3641B1 (ar) 2020-08-27

Family

ID=48468655

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0141A JO3641B1 (ar) 2012-05-03 2013-05-05 تركيبة مضادات الفيروسات القهقرية

Country Status (13)

Country Link
US (1) US20150086628A1 (ar)
EP (1) EP2844231A1 (ar)
JP (1) JP6314131B2 (ar)
KR (1) KR20150021510A (ar)
CN (1) CN104411300A (ar)
AU (1) AU2013255666A1 (ar)
CA (1) CA2871794A1 (ar)
IN (1) IN2014MN02252A (ar)
JO (1) JO3641B1 (ar)
MX (1) MX2014013326A (ar)
RU (1) RU2014148964A (ar)
WO (1) WO2013164559A1 (ar)
ZA (1) ZA201408281B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2663466C1 (ru) * 2017-03-20 2018-08-06 Общество с ограниченной ответственностью "МБА-групп" Композиция для профилактики и/или лечения вич-инфекции
CN112220771B (zh) * 2020-11-10 2023-03-31 成都大学 扎西他滨渗透泵型控释片及其制备方法
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226822A (en) * 1987-11-16 1990-03-27 Mcneil Consumer Prod Chewable medicament tablet containing means for taste masking
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
JP3693270B2 (ja) * 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MXPA03010771A (es) 2001-05-25 2004-07-01 Abbott Lab Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AR050230A1 (es) * 2004-02-06 2006-10-11 Wyeth Corp Sales de o-desmetilvenlafaxina de multiples particulas y sus usos
US7709025B2 (en) * 2004-03-31 2010-05-04 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
TW200815033A (en) * 2006-08-10 2008-04-01 Cipla Ltd Antiretroviral solid oral composition
JP5285709B2 (ja) * 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
WO2011141192A1 (en) * 2010-05-10 2011-11-17 Evonik Röhm Gmbh Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
WO2013057469A1 (en) * 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions

Also Published As

Publication number Publication date
MX2014013326A (es) 2015-08-10
RU2014148964A (ru) 2016-06-27
CN104411300A (zh) 2015-03-11
CA2871794A1 (en) 2013-11-07
JP6314131B2 (ja) 2018-04-18
AU2013255666A1 (en) 2014-11-20
KR20150021510A (ko) 2015-03-02
EP2844231A1 (en) 2015-03-11
IN2014MN02252A (ar) 2015-07-24
ZA201408281B (en) 2019-06-26
US20150086628A1 (en) 2015-03-26
JP2015519326A (ja) 2015-07-09
WO2013164559A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
EP3356521A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
EP3407918A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
EP3302709A4 (en) METHODS AND COMPOSITIONS RNA-GUIDED TREATMENT OF HIV INFECTIONS
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
EP3038661A4 (en) Methods and compositions for rna-guided treatment of hiv infection
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2014011825A (es) INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
PH12015501156A1 (en) Pharmaceutical compositions
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
IN2013MU01749A (ar)
PH12016500492A1 (en) Pyridazinone compounds and uses thereof
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2013173759A3 (en) Macrocyclic nucleoside phosphoramidate derivatives
EP2699584A4 (en) CYCLIC PEPTIDE FROM NONOMURAEA SP., METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MICRO-BACTERIA-INFLAMMATED DISEASES THEREWITH
GB2498276B (en) Medicinal agent and mode of prevention of HIV contamination, prevention and treatment of diseases caused by HIV and HIV-associated diseases including AIDS.
AU2012280198A8 (en) Darunavir combination formulations
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
TN2017000109A1 (en) Stabilized adrenomedullin derivatives and use thereof
IN2014MU00916A (ar)
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
JO3641B1 (ar) تركيبة مضادات الفيروسات القهقرية